N/A N=200 Efficacy Safety Score in Postoperative Management
Pain, Postoperative · Postoperative Nausea and Vomiting
Primary: Time to Mobilization — 10.1; 14.2 hours
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 Subcutaneous Fat Reduction in the Submental Area
Body Fat Disorder
Primary: Safety of CoolScupting in the Submental Area — 4 incidence of device- and/or procedure AE
Phase 2 N=95 Dose Ranging Study of OTO-201 in AOMT
Acute Otitis Media · AOMT
Primary: Number of Subjects With Adverse Events — 19; 14; 4 Participants
Phase 2 N=6 Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD
Eosinophilic Esophagitis · Connective Tissue Disorders
Primary: Percent of Participants in Histologic Remission at 16 Weeks — 17; 17 percentage of participants
N/A N=19 Fat Layer Reduction in the Lateral Thighs Using CoolSculpting
Body Fat Disorder
Primary: Safety of the Zeltiq CoolSculpting System in the Outer Thighs — 8; 0 events
N/A N=15 Circadian Macular Volume Changes in the Choroid
Choroid Physiology
Primary: Macular Choroidal Volume — 10.33 mm^3
N/A N=79 ThermoSmart® Versus Conventional Humidification in Continuous Positive Airway Pressure (CPAP)
Sleep Apnea, Obstructive
Primary: CPAP Compliance
Phase 3 N=768 A Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute Pain
Acute Pain
Primary: Number of Patients That Experienced a Treatment-emergent Adverse Event — 490 Participants
N/A N=260 LUME BioNIS: a Biomarker Study in Patients With NSCLC
Carcinoma, Non-Small-Cell Lung
Primary: Number of Participants With Overall Survival (OS) Event — 206 Participants
N/A N=51 Healthy Living Partnerships to Prevent Diabetes in Veterans Pilot Study
Pre-diabetes · Obesity
Primary: Recruitment of Study Participants — 58; 51 Participants
N/A N=68 Comparison of Hydro-dissection Versus Ultrasonic Aspirator in Division of Liver Parenchyma in Laparoscopic Resection
Liver Transection During Laparoscopic Liver Resection
Primary: Intraoperative Blood Loss — 195; 218 ml
N/A N=210 Applying Mobile Persuasive Technologies to Increase Physical Activity in Women
Sedentary Lifestyle · Physical Activity
Primary: Accelerometer (Omron Active Style Pro HJA-350IT) Measured Daily Steps — 5837; 5063; 5384; 8709 Steps/Day
Phase 2 N=120 An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)
Myelodysplastic Syndromes · Leukemia, Myelomonocytic, Chronic · Leukemia, Myeloid, Acute
Primary: Overall Survival (OS) — 19.0; 21.8 months — p=0.464
Phase 4 N=48 Tolvaptan in Hyponatremic Cancer Patients
Advanced Cancers
Primary: Participants Whose Serum Sodium Concentration Corrected to at Least 135 mEq/L on Day 14 — 16; 1 participants
Phase 2 N=36 Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer
Breast Cancer
Primary: Progression-free Survival — 4.3 months